Research: Sun Ten Gentiana Combination Effectively Treats Eosinophilic Meningitis When Combined with Albendazole
Comparative Efficacies of Albendazole and the Chinese Herbal Medicine
Long-Dan-Xie-Gan-Tan, Used Alone or in Combination, in the Treatment of
Experimental Eosinophilic Meningitis Induced by Angiostrongylus Cantonensis
S. C. Lai, K. M. Chen, Y.H. Chang, and H. H. Lee
Abstract
Angiostrongylus cantonensis, the rat lungworm, is the principal cause of human eosinophilic meningitis or meningoencephalitis world-wide. In the present study, the efficacies of early-stage treatment with the Chinese herbal medicine long-dan-xie-gan-tan (LDXGT) and albendazole, used alone or in combination, were evaluated in BALB/c mice with A. cantonensis-induced dysfunction of the blood-central-nervous-system barrier and eosinophilic meningo-encephalitis. Indicators of the therapeutic effect included worm recovery, histopathological scores for the meningitis, assays of tissue-type plasminogen activator (PA), urokinase-type PA and matrix metalloproteinase-9 (MMP-9) in the brain, the ratio between albumin concentrations in the cerebrospinal fluid (CSF) and serum, and counts of eosinophils in the CSF.
Combined treatment with albendazole and LDXGT gave better results than monotherapy based on either drug, apparently inhibiting eosinophilic meningitis via antagonists of the PA/MMP-9 system. LDXGT may have a therapeutic role in reducing inflammatory reaction in the subarachnoid space. Monotherapy with such an anti-inflammatory drug may relieve the symptoms of mild infection and the host’s immune responses to A. cantonensis larvae. In severe infection, however, co-therapy with an anthelmintic (to kill the larvae) and an anti-inflammatory agent (to provide symptomatic relief) is probably a better approach. The therapeutic strategy should be tailored to the severity of the illness and the numbers of eosinophils in the CSF.
- Introduction
- Animals and Methods
- Experimental Animals
- Larval Preparation
- Drugs: The albendazole used was purchased, as Zentel®, from GlaxoSmithKline (Brentford, U.K.) whereas the LDXGT was bought from Sun Ten Pharmaceutical (Taipei, Taiwan)
- Treatments
- Brain Studies
- PCR
- CSF Studies and Serology
- Statistical Analysis
- Experimental Animals
- Results
- Larval Recovery and Biochemical Factors
- Histology
- Larval Recovery and Biochemical Factors
- Discussion
- References
Join our member to get full-text article! Join Free!